drugset / Trial / NCT01623284

PiB PET Scanning in Speech and Language Based Dementias

NCT01623284

Phase 1 Completed 168 enrolled Mayo Clinic
NaSingle-groupOpen-labelDiagnostic

Summary

The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.

Timeline

Start
2010-03
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject C-11 PiB Diagnostic / imaging agent 740 mbq Intravenous
Subject F-18 FDG Diagnostic / imaging agent 629 mbq Intravenous